

# Novel Anti-Microtubule Cancer Therapeutics



## BPH Corporate Ltd

BPH Corporate manages a strong portfolio of biomedical technologies emerging from research by leading Universities, Medical Institutes and Hospitals across Australia.

The company provides product development and commercial direction, whilst the institutional partner provides the majority of the infrastructure and research expertise.

Technologies on the way to commercialisation include diagnosis of infectious disease, brain function monitoring, pre-clinical molecules for use in oncology, metabolic, neurodegenerative and infectious disease.

BPH has a balanced management system combining corporate and scientific expertise.

The company's head office is based in Perth, Western Australia and is listed on the Australian Securities Exchange with ASX code BPH.

## Australian Research Network



The Australian Research Network represents BPH Corporate Limited.

The Australian Research Network is a technology transfer company based in Los Angeles focused on the commercialisation of early stage technologies from Australia.

The Australian Research Network is a wholly owned subsidiary of TM Ventures Pty Ltd, a business development company based in Sydney Australia.

**BPH Corporate is expanding its search for a suitable drug development partner for its drug validation program.**

## Background

Microtubule drugs directly block cell proliferation, thereby causing cancer cell death (Figure 1A). As a result of their ability to kill rapidly dividing cancerous cells, microtubule drugs such as Taxol® are among the most clinically useful cancer therapeutics discovered to date, generating revenue will in excess of one billion USD per year.

Several more recently developed microtubule drugs can also target tumours by disruption of the tumour vasculature (Figure 1B). Microtubule drugs (e.g. Zybrestat and Ombrabulin) that target the tumour vasculature are currently undergoing extensive clinical development and testing.

## Data

The new microtubule drug BPH 8 can disrupt adhesions between vascular endothelial cells. As a result of medicinal chemistry by Epichem, a drug with low nanomolar activity has progressed to *in vivo* testing of anti-tumour activity.




Figure 1

Figure 1A

## Our Technology

BPH has recently identified new anti-cancer agents that inhibit cancer cell proliferation by targeting of the microtubule cytoskeleton (Figure 2).

Currently in the proof of-concept stage, the project is utilizing the Molecular Discovery Systems InCell Analyser high-content platform for cell-based investigations, as well as *in vivo* trials of tumour growth.




Figure 2

$\beta$ -tubulin/DNA

BPH is actively engaged with Epichem in pharmaceutical development of clinically suitable forms of the new anti-cancer drug BPH 8.

## For Further Information



David Breeze  
Chairman  
BPH Corporate Limited  
T +61 8 9328 8366  
david@bphcorporate.com.au  
www.bphcorporate.com.au

Matt Harris PhD  
Managing Director  
TM Ventures  
T +61 439 620 125  
mharris@tmventures.com.au  
www.tmventures.com.au